Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.


Griffith R Harsh, IV, MD, MBA
Lawrence D Recht, MD
Karen J Marcus, MD
Section Editors
Jay S Loeffler, MD
Patrick Y Wen, MD
Amar Gajjar, MD
Deputy Editor
April F Eichler, MD, MPH


Craniopharyngiomas are rare solid or mixed solid-cystic tumors that arise from remnants of Rathke's pouch along a line from the nasopharynx to the diencephalon [1]. Historically, these have also been referred to as Rathke pouch tumors or hypophyseal duct tumors.

The epidemiology, pathology, diagnosis, management, and outcomes after treatment of craniopharyngiomas are reviewed here.


In the United States, there are an estimated 350 new cases of craniopharyngioma diagnosed each year, constituting approximately 1 to 3 percent of all brain tumors [2,3]. Craniopharyngiomas comprise approximately 5 to 10 percent of brain tumors in children [3,4]. In other parts of the world, craniopharyngiomas appear to be more common, with higher incidence rates reported in Japan and some parts of Africa [5,6]. Craniopharyngiomas are approximately equally common in males and females.

There is a bimodal age distribution, with one peak in children between 5 and 14 years, and a second peak in adults between 50 and 75 years of age [2]. Adamantinomatous craniopharyngiomas are more common in the pediatric age group, while papillary craniopharyngiomas are seen predominantly in adults [7]. (See 'Pathology and molecular genetics' below.)


Craniopharyngiomas are epithelial tumors that usually arise in the pituitary stalk in the suprasellar region, adjacent to the optic chiasm. A small percentage arise within the sella [8,9], and a few tumors have been described within the optic system or the third ventricle [10-12].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Oct 18, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Petito CK, DeGirolami U, Earle KM. Craniopharyngiomas: a clinical and pathological review. Cancer 1976; 37:1944.
  2. Bunin GR, Surawicz TS, Witman PA, et al. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998; 89:547.
  3. Jane JA Jr, Laws ER. Craniopharyngioma. Pituitary 2006; 9:323.
  4. Garrè ML, Cama A. Craniopharyngioma: modern concepts in pathogenesis and treatment. Curr Opin Pediatr 2007; 19:471.
  5. Stiller CA, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol 1994; 23:458.
  6. Izuora GI, Ikerionwu S, Saddeqi N, Iloeje SO. Childhood intracranial neoplasms Enugu, Nigeria. West Afr J Med 1989; 8:171.
  7. WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.
  8. Laws ER Jr. Transsphenoidal microsurgery in the management of craniopharyngioma. J Neurosurg 1980; 52:661.
  9. NORTHFIELD DW. Rathke-pouch tumours. Brain 1957; 80:293.
  10. Rush JA, Younge BR, Campbell RJ, MacCarty CS. Optic glioma. Long-term follow-up of 85 histopathologically verified cases. Ophthalmology 1982; 89:1213.
  11. Bollati A, Giunta F, Lenzi A, Marini G. Third ventricle intrinsic craniopharingioma. Case report. J Neurosurg Sci 1974; 18:216.
  12. Cashion EL, Young JM. Intraventricular craniopharyngioma. Report of two cases. J Neurosurg 1971; 34:84.
  13. Buslei R, Nolde M, Hofmann B, et al. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 2005; 109:589.
  14. Sekine S, Shibata T, Kokubu A, et al. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 2002; 161:1997.
  15. Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014; 46:161.
  16. Weiner HL, Wisoff JH, Rosenberg ME, et al. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 1994; 35:1001.
  17. Crotty TB, Scheithauer BW, Young WF Jr, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 1995; 83:206.
  18. Duff J, Meyer FB, Ilstrup DM, et al. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 2000; 46:291.
  19. Garnett MR, Puget S, Grill J, Sainte-Rose C. Craniopharyngioma. Orphanet J Rare Dis 2007; 2:18.
  20. Khan RB, Merchant TE, Boop FA, et al. Headaches in children with craniopharyngioma. J Child Neurol 2013; 28:1622.
  21. Lober RM, Harsh GR 4th. A perspective on craniopharyngioma. World Neurosurg 2013; 79:645.
  22. Honegger J, Tatagiba M. Craniopharyngioma surgery. Pituitary 2008; 11:361.
  23. de Divitiis E, Cappabianca P, Cavallo LM, et al. Extended endoscopic transsphenoidal approach for extrasellar craniopharyngiomas. Neurosurgery 2007; 61:219.
  24. Cohen M, Bartels U, Branson H, et al. Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011. Neuro Oncol 2013; 15:767.
  25. Elowe-Gruau E, Beltrand J, Brauner R, et al. Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 2013; 98:2376.
  26. Minniti G, Esposito V, Amichetti M, Enrici RM. The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngioma. Neurosurg Rev 2009; 32:125.
  27. Jalali R, Gupta T, Goda JS, et al. Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial. JAMA Oncol 2017; 3:1368.
  28. Combs SE, Thilmann C, Huber PE, et al. Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer 2007; 109:2308.
  29. Kobayashi T. Long-term results of gamma knife radiosurgery for 100 consecutive cases of craniopharyngioma and a treatment strategy. Prog Neurol Surg 2009; 22:63.
  30. Niranjan A, Kano H, Mathieu D, et al. Radiosurgery for craniopharyngioma. Int J Radiat Oncol Biol Phys 2010; 78:64.
  31. Fitzek MM, Linggood RM, Adams J, Munzenrider JE. Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 2006; 64:1348.
  32. Luu QT, Loredo LN, Archambeau JO, et al. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J 2006; 12:155.
  33. Bishop AJ, Greenfield B, Mahajan A, et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys 2014; 90:354.
  34. Regine WF, Kramer S. Pediatric craniopharyngiomas: long term results of combined treatment with surgery and radiation. Int J Radiat Oncol Biol Phys 1992; 24:611.
  35. Habrand JL, Ganry O, Couanet D, et al. The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. Int J Radiat Oncol Biol Phys 1999; 44:255.
  36. Varlotto JM, Flickinger JC, Kondziolka D, et al. External beam irradiation of craniopharyngiomas: long-term analysis of tumor control and morbidity. Int J Radiat Oncol Biol Phys 2002; 54:492.
  37. McMurry FG, Hardy RW Jr, Dohn DF, et al. Long term results in the management of craniopharyngiomas. Neurosurgery 1977; 1:238.
  38. Ignelzi RJ, Squire LR. Recovery from anterograde and retrograde amnesia after percutaneous drainage of a cystic craniopharyngioma. J Neurol Neurosurg Psychiatry 1976; 39:1231.
  39. Gutin PH, Klemme WM, Lagger RL, et al. Management of the unresectable cystic craniopharyngioma by aspiration through an Ommaya reservoir drainage system. J Neurosurg 1980; 52:36.
  40. Manaka S, Teramoto A, Takakura K. The efficacy of radiotherapy for craniopharyngioma. J Neurosurg 1985; 62:648.
  41. Huk WJ, Mahlstedt J. Intracystic radiotherapy (90Y) of craniopharyngiomas: CT-guided stereotaxic implantation of indwelling drainage system. AJNR Am J Neuroradiol 1983; 4:803.
  42. Julow J, Lányi F, Hajda M, et al. The radiotherapy of cystic craniopharyngioma with intracystic installation of 90Y silicate colloid. Acta Neurochir (Wien) 1985; 74:94.
  43. Voges J, Sturm V, Lehrke R, et al. Cystic craniopharyngioma: long-term results after intracavitary irradiation with stereotactically applied colloidal beta-emitting radioactive sources. Neurosurgery 1997; 40:263.
  44. Pollock BE, Lunsford LD, Kondziolka D, et al. Phosphorus-32 intracavitary irradiation of cystic craniopharyngiomas: current technique and long-term results. Int J Radiat Oncol Biol Phys 1995; 33:437.
  45. Backlund EO, Johansson L, Sarby B. Studies on craniopharyngiomas. II. Treatment by stereotaxis and radiosurgery. Acta Chir Scand 1972; 138:749.
  46. Van den Berge JH, Blaauw G, Breeman WA, et al. Intracavitary brachytherapy of cystic craniopharyngiomas. J Neurosurg 1992; 77:545.
  47. Barriger RB, Chang A, Lo SS, et al. Phosphorus-32 therapy for cystic craniopharyngiomas. Radiother Oncol 2011; 98:207.
  48. Zhang S, Fang Y, Cai BW, et al. Intracystic bleomycin for cystic craniopharyngiomas in children. Cochrane Database Syst Rev 2016; 7:CD008890.
  49. Hukin J, Steinbok P, Lafay-Cousin L, et al. Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience. Cancer 2007; 109:2124.
  50. Kilday JP, Caldarelli M, Massimi L, et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol 2017; 19:1398.
  51. Cavalheiro S, Dastoli PA, Silva NS, et al. Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma. Childs Nerv Syst 2005; 21:719.
  52. Cavalheiro S, Di Rocco C, Valenzuela S, et al. Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus 2010; 28:E12.
  53. Shi XE, Wu B, Fan T, et al. Craniopharyngioma: surgical experience of 309 cases in China. Clin Neurol Neurosurg 2008; 110:151.
  54. Elliott RE, Hsieh K, Hochm T, et al. Efficacy and safety of radical resection of primary and recurrent craniopharyngiomas in 86 children. J Neurosurg Pediatr 2010; 5:30.
  55. Stripp DC, Maity A, Janss AJ, et al. Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. Int J Radiat Oncol Biol Phys 2004; 58:714.
  56. Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005; 62:397.
  57. Lin LL, El Naqa I, Leonard JR, et al. Long-term outcome in children treated for craniopharyngioma with and without radiotherapy. J Neurosurg Pediatr 2008; 1:126.
  58. Mark RJ, Lutge WR, Shimizu KT, et al. Craniopharyngioma: treatment in the CT and MR imaging era. Radiology 1995; 197:195.
  59. Honegger J, Buchfelder M, Fahlbusch R. Surgical treatment of craniopharyngiomas: endocrinological results. J Neurosurg 1999; 90:251.
  60. Fahlbusch R, Honegger J, Paulus W, et al. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 1999; 90:237.
  61. Olsson DS, Andersson E, Bryngelsson IL, et al. Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab 2015; 100:467.
  62. Lo AC, Howard AF, Nichol A, et al. Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience. Int J Radiat Oncol Biol Phys 2014; 88:1011.
  63. Hoffmann A, Bootsveld K, Gebhardt U, et al. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. Eur J Endocrinol 2015; 173:389.
  64. Fjalldal S, Holmer H, Rylander L, et al. Hypothalamic involvement predicts cognitive performance and psychosocial health in long-term survivors of childhood craniopharyngioma. J Clin Endocrinol Metab 2013; 98:3253.
  65. Özyurt J, Müller HL, Thiel CM. A systematic review of cognitive performance in patients with childhood craniopharyngioma. J Neurooncol 2015; 125:9.
  66. Müller HL, Bruhnken G, Emser A, et al. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Childs Nerv Syst 2005; 21:975.
  67. Ahmet A, Blaser S, Stephens D, et al. Weight gain in craniopharyngioma--a model for hypothalamic obesity. J Pediatr Endocrinol Metab 2006; 19:121.
  68. Lipton J, Megerian JT, Kothare SV, et al. Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma. Neurology 2009; 73:323.
  69. van der Klaauw AA, Biermasz NR, Pereira AM, et al. Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. Clin Endocrinol (Oxf) 2008; 69:769.
  70. Dolson EP, Conklin HM, Li C, et al. Predicting behavioral problems in craniopharyngioma survivors after conformal radiation therapy. Pediatr Blood Cancer 2009; 52:860.
  71. Liu AK, Bagrosky B, Fenton LZ, et al. Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer 2009; 52:227.
  72. Lo AC, Howard AF, Nichol A, et al. A Cross-Sectional Cohort Study of Cerebrovascular Disease and Late Effects After Radiation Therapy for Craniopharyngioma. Pediatr Blood Cancer 2016; 63:786.
  73. Enchev Y, Ferdinandov D, Kounin G, et al. Radiation-induced gliomas following radiotherapy for craniopharyngiomas: a case report and review of the literature. Clin Neurol Neurosurg 2009; 111:591.
  74. Wisoff JH. Surgical management of recurrent craniopharyngiomas. Pediatr Neurosurg 1994; 21 Suppl 1:108.
  75. Rodriguez FJ, Scheithauer BW, Tsunoda S, et al. The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol 2007; 31:1020.
  76. Boongird A, Laothamatas J, Larbcharoensub N, Phudhichareonrat S. Malignant craniopharyngioma; case report and review of the literature. Neuropathology 2009; 29:591.
  77. Lermen O, Frank S, Hassler W. Postoperative spinal recurrence of craniopharyngioma. Acta Neurochir (Wien) 2010; 152:309.
  78. Elliott RE, Moshel YA, Wisoff JH. Surgical treatment of ectopic recurrence of craniopharyngioma. Report of 4 cases. J Neurosurg Pediatr 2009; 4:105.
  79. Frangou EM, Tynan JR, Robinson CA, et al. Metastatic craniopharyngioma: case report and literature review. Childs Nerv Syst 2009; 25:1143.
  80. Romani R, Niemelä M, Celik O, et al. Ectopic recurrence of craniopharyngioma along the surgical route: case report and literature review. Acta Neurochir (Wien) 2010; 152:297.
  81. Visser J, Hukin J, Sargent M, et al. Late mortality in pediatric patients with craniopharyngioma. J Neurooncol 2010; 100:105.